The effect of ST1942, a 2-aminotetraline derivative with anti-inflammatory properties, was evaluated in ischemia/reperfusion injury in CD1 and C57BL/6 mice. ST1942 or saline were injected intraperitoneally 30 min and 6, 24, 36 h after ischemia. Forty-eight hours after ischemia, ST1942 (25 mg/kg) reduced the infarct volume by 50% in CD1 and 61% in C57BL/6 mice. All subsequent data were obtained from the latter strain. The ischemic lesion was significantly reduced by 30% when the first injection was administered 6 h after ischemia, revealing a broad effective window. Degenerating neurons in striatum, cortex and hippocampus of ischemic mice were markedly decreased by ST1942. Also examined was the effect of ST1942 on general and focal neurological deficits for 4 days after ischemia. Mice receiving the drug twice daily showed constantly reduced deficits. We then investigated the cortical mRNA expression of some inflammatory and apoptotic genes by real-time PCR. Forty-eight hours after ischemia ST1942 treatment significantly counteracted ischemia-induced activation of IL-1b, TNFa, and Bax, and enhanced the expression of the antiapoptotic gene, Bcl-2, showing in vivo anti-inflammatory and antiapoptotic actions. The microglial activation/macrophage recruitment in the ischemic lesion was strongly prevented in mice receiving ST1942. In neuron-microglia cocultures, ST1942 significantly counteracted LPS-induced cytotoxicity. Binding data and experiments on microglial cell cultures indicate that the anti-inflammatory effect of ST1942 may be due to its action on 5-HT2B receptors, thus highlighting the possibility that this 5-HT receptor subtype may represent a novel target for neuroprotective drugs in ischemic injury.
INTRODUCTION
The inflammatory response is a major mechanism in the pathogenesis of brain ischemia/reperfusion injury and represents an interesting target for therapeutic interventions (Allan and Rothwell, 2001; del Zoppo et al, 2000; Dirnagl et al, 1999; Iadecola and Alexander, 2001) . At variance with excitotoxicity, which is disruptive but of brief duration, the inflammatory response, after being rapidly triggered, progresses over many hours. It contributes to the evolution of tissue injury by several possible pathways, leading ultimately to activation of apoptotic mechanisms. Soon after ischemia, several inflammatory cascades are initiated. Vascular endothelial cells become rapidly activated, leading to rapid upregulation of adhesion molecules (Connolly et al, 1996; Frijns and Kappelle, 2002; Pantoni et al, 1998; Storini et al, 2005) . Resident cellular populations, namely astrocytes and microglia, and recruited inflammatory cells, such as neutrophils and macrophages, are triggered to produce an array of inflammatory molecules, including pro-inflammatory cytokines that profoundly affect the pathogenesis of brain injury (Frijns and Kappelle, 2002; Touzani et al, 1999) .
Aminotetraline derivatives have previously been reported to possess anti-inflammatory activity, being able to counteract LPS-induced lethality, and cytokine and nitric oxide production (Ruggiero et al, 2004) . This in vivo protective effect was possibly mediated by an action on peripheral mononuclear cells. These data indicate that 2-aminotetraline derivatives may represent novel drugs effective in antiinflammatory strategies.
We set out to determine the effect of ST1942, a 2-aminotetraline derivative with anti-inflammatory properties (Piovesan et al, 2003) , in a mouse model of ischemia with reperfusion. Indeed, reperfusion, which occurs in human ischemia either spontaneously or as a result of pharmacological thrombolysis, has several important effects on the extent of tissue injury and recovery, particularly with regard to inflammatory events, as it allows the migration of inflammatory cells to the site of injury, thus sustaining the inflammatory response. Ischemia was induced in outbred and inbred mouse strains (CD1 and C57BL/6, respectively). The protective effect of different treatment schedules was assessed. The mRNA expression of some inflammatory and apoptotic genes by real-time PCR and the effect on microglial/macrophages were also investigated. In vitro, the ability of ST1942 to counteract LPS-induced toxicity on neuron-microglia cocultures was evaluated. Furthermore, as binding studies indicate that ST1942 binds to 5-HT2B receptors, its effect and that of 5-HT2B agonists and antagonists was explored on LPS-induced TNF-a release from microglial cells providing further details on the possible mechanism of ST1942 neuroprotective action.
MATERIALS AND METHODS

Animals
Male C57BL/6 and CD1 mice (26-28 g, Charles River, Calco, Italy) were housed five per cage and kept at constant temperature (21711C) and relative humidity (60%) with regular light/dark schedule (0700-1900 hours). Food (Altromin pellets for mice) and water were available ad libitum.
Procedures involving animals and their care were conducted in conformity with institutional guidelines that are in compliance with national (DL n116, GU suppl. 40, 18 February 1992) 
Transient Focal Cerebral Ischemia
Ischemia was achieved by middle cerebral artery occlusion as described previously De Simoni et al, 2003) . Anesthesia was induced by 5% isoflurane in N 2 O/O 2 (70/30%) mixture and maintained by 1.5-2% isoflurane in the same mixture. To confirm the adequacy of the vascular occlusion in each animal, blood flow was measured by laser Doppler flowmetry (Transonic BLF-21) using a flexible 0.5 mm fiberoptic probe (Transonic, Type M, 0.5 mm diameter) positioned on the brain surface and secured with impression material on the skull at the following coordinates: AP ¼ À1 mm; L ¼ À3.5 mm. Briefly, the right common carotid artery was exposed and the external carotid artery and its branches, including the occipital artery and the superior thyroid artery, were isolated and cauterized. The pterytopalatine artery was ligated and the external carotid artery cauterized. A 6-0 monofilament nylon suture, blunted at the tip by heat and coated in poly-L-lysine, was introduced into the internal carotid artery through the external carotid artery stump and advanced to the anterior cerebral artery so as to block its bifurcation into the anterior cerebral artery and the MCA. The filament was advanced until a 470% reduction of blood flow, compared to preischemic baseline, was observed. At the end of a 15 min (in C57BL/6 mice) or 30 min (in CD1 mice) ischemic period, blood flow was restored by carefully removing the nylon filament. During surgery, mice maintained at constant temperature (3770.51C) using a heating pad equipped with a rectal probe (LSI-Letica, Spain).
Sham-Operated Mice
Sham-operated mice received a midline neck incision, and the carotid sheath was exposed. The external carotid artery and its branches were isolated without being ligated or cauterized. Similar to ischemic mice, sham-operated mice were maintained at 371C during surgery and recovery from anesthesia.
Drug Treatment
Mice were injected intraperitoneally (i.p.) with 6.25, 12.5, and 25 mg/kg of ST1942 ((2S)-(À)-7-acetyl-6-methyl-1,2,3,4-tetrahydro-2-naphtalenaminium-chloride, SigmaTau, Pomezia, Italy) or saline according to different administration schedules (times are calculated from the beginning of ischemia): (A) four doses at 30 min, 6, 24, and 36 h; (B) four doses at 2, 6, 24, and 36 h; (C) four doses at 4, 8, 24, and 36 h; (D) four doses at 6, 10, 24, and 36 h; (E) four doses at 8, 12, 24, and 36 h; (F) one dose at 30 min; (G) eight doses, starting at 30 min and 6, 24, 36, 48, 60, 72, 84 h (ie twice a day for 4 days); (H) two doses at 30 min and 6 h.
Quantification of Infarct Size and Volume
Mice were deeply anesthetized with Equitensin (120 ml/mice i.p.) and brains were rapidly frozen by immersion in isopentane at À451C for 3 min before being sealed into vials and stored at À701C until use. For lesion size determination, 40 mm coronal brain sections were serially cut at 320 mm intervals and stained with neutral red (Neutral Red Gurr Certistain, BDH, England) . On each slice, infarcted areas were assessed blindly and delineated by the relative paleness of histological staining. The infarcted area was determined by subtracting the area of the healthy tissue in the ipsilateral hemisphere from the area of the contralateral hemisphere on each section. Infarct volumes were calculated by the integration of infarcted areas on each brain slice as quantified with computerassisted image analyzer and calculated by Analytical Image System.
Neurological Deficits
Each mouse was rated once a day on two neurological function scales unique to the mouse (Clark et al, 1997; De Simoni et al, 2004) . Mice were scored on both scales from 0 (healthy mouse) to 28. The score given represents the sum of the results of all categories for each scale. General deficit scale evaluated: hair, ears, eyes, posture, spontaneous activity, epileptic behavior. Focal deficit scale evaluated: body symmetry, gait, climbing onto a surface held at 451, circling behavior, front limb symmetry, compulsory circling, whisker response to a light touch. All the experiments were run by a trained investigator blinded to the experimental conditions. Differences between ischemic mice receiving ST1942 or saline were analyzed by Friedman test.
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Brain Transcardial Perfusion
Mice were deeply anesthetized with Equitensin (120 ml/ mouse i.p.) and transcardially perfused with 20 ml PBS 0.1 mol/l, pH 7.4, followed by 50 ml of chilled paraformaldheyde (4%) in PBS. After carefully removing brains from skulls, they were transferred to 30% sucrose in PBS at 41C overnight for cryoprotection. Brains were then rapidly frozen by immersion in isopentane at À451C for 3 min, sealed into vials and stored at À701C until use.
Fluoro-Jade Labeling
Fluoro-Jade labeling was carried out on perfused brains Schmued et al, 1997) . Briefly, 20 mm mounted sections were dried and dehydrated in ethanol (100-75%) and distilled water. They were then incubated in 0.06% potassium permanganate, washed in distilled water and transferred to 0.001% Fluoro-Jade staining solution. After staining, the sections were rinsed in distilled water, dried, immersed in xylene, and coverslipped.
Immunohistochemistry
Twenty-micrometer-thick coronal sections were used for microglia/macrophages immunostaining. Briefly, the sections were rinsed for 30 min in 0.4% Triton X-100 in 0.1 mol/l PBS followed by 15 min in 0.1% Triton X-100 and 3% normal goat serum in PBS. The sections were then incubated overnight with the primary monoclonal antibody CD11b, a marker for microglia and macrophages (1:300, a kind gift of Dr A Doni, Mario Negri Institute, Milan, Italy). The next day, the sections were rinsed in PBS before incubation with biotinylated goat anti-mouse secondary antibody for 1 h, washed and incubated with avidin-biotin complex (ABC kit, Vector, UK). After reacting with 3,3 0 -diaminobenzidine tetrahydrochloride (DAB, Vector) the sections were washed, dried, dehydrated through graded alcohols, fixed in xylene, and coverslipped using DPX mountant before light microscopy analysis.
Immunopositive cells were counted in striatum by an image analysis software (AnalySIS). For each mouse three sections, corresponding to coordinates À1.10 mm, À0.70 mm, and À0.20 mm from bregma, were considered. In each slice, six fields at Â 20 were counted. Results are expressed as ratio between immunostained area and the total area of the fields assessed (100%).
RNA Isolation, cDNA Synthesis, and Real-Time PCR Total RNA was isolated from lesioned side cortex according to the acid guanidium-phenol-chloroform method, as shown previously (De Simoni et al, 2000) . Complementary DNA was synthesized as follows: 2 mg total RNA from each sample was reverse transcribed with random hexamer primers using Multi-Scribe Reverse Transcriptase (TaqMan Reverse transcription reagents, Applied Biosystems, Foster City, CA). The following thermal cycling protocol for reverse transcription was used: 10 min at 251C for incubation, 30 min at 481C for reverse transcription, and then 5 min at 951C for inactivation. Real-time PCR was performed using a GeneAmp 5700 Sequence detection System (Applied Biosystems, Foster City, CA). Fifty nanograms of cDNA and gene-specific primers (200 nmol/l final concentration) were added to Master Mix SYBR Green I Dye, TaqMan DNA polymerase, dNTPs with dUTP, and optimal buffer components (Applied Biosystems, Foster City, CA) and subjected to PCR amplification in a total volume of 25 ml. The PCR protocol included one cycle at 501C for 2 min, one cycle at 951C for 10 min, 40 cycles at 951C for 15 s and 601C for 1 min. Real-time PCR was conducted in triplicate with each RNA sample. The amplified transcripts were quantified using the comparative cycle threshold method (Applied Biosystems users bulletin no. 2). Primer optimizing procedures and validation experiments (data not shown) were performed according to the manufacturer's instructions to show that efficiency of target and reference was equal. b-Actin was used as reference gene and relative gene expression levels were determined according to manufacturer's DDC t method (Applied Biosystems). Primers were designed using Primer Express software (Applied Biosystems, Foster City, CA) based on GenBank accession numbers (Table 1) .
Binding assays
]DOI binding assays. CHO cells transfected with human serotonin 5HT2B receptors were used and DOI binding assay was performed as described previously (Choi et al, 1994) . Briefly, the incubation medium (200 ml) contained 50 ml of radioligand (0.2 nM of DOI), 50 ml of buffer (50 mmol/l Tris buffer, pH 7.4) alone or containing competing drug, and 100 ml of membrane suspension (protein concentration, 50 mg/ml). The mixture was incubated at 371C for 15 min. Nonspecific binding, determined in the presence of 1 mmol/l unlabeled DOI, represented about 30% of total binding.
Competition studies for DOI binding were performed by adding increasing concentrations (8 points from 3.0EÀ08 to 1.0EÀ04 mol/l) of ST1942 to the reaction.
The IC 50 values and Hill coefficients (n H ) were determined by nonlinear regression analysis of the competition curves using Hill equation curve fitting. As the Hill Table 1 Primers used for quantitative real-time polymerase chain reaction analysis of b actin, TNF-a, IL-1 b, Bcl-2, and Bax transcript levels
fwd, forward; rev, reverse primers. 
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Cell Cultures
Primary microglial cells were derived from postnatal days 3-4 rat cortex as described previously (Aloisi et al, 1998; Novarino et al, 2004) . Free-floating microglia were collected from shaken astrocyte flasks, seeded onto 24-well plates (3 Â 10 5 cells/well) and maintained in DMEM (Invitrogen, Milan, Italy) supplemented with 10% fetal calf serum (FCS) (Invitrogen, Milan, Italy) in 5% CO2. The purity of microglial cultures was assessed by a positive staining for Griffonia simplicifolia isolectin B4 (Vector Laboratories, Burlingame, CA). The murine microglial cell line BV-2 (Blasi et al, 1990) was grown in DMEM supplemented with 10% FCS in 5% CO 2 .
Microglial primary cultures or BV-2 cells were treated for 1 h with 50 ng/ml Escherichia coli LPS alone or in combination with 0.01, 0.1, 1, 10 mmol/l ST1942, SB204741 (5-HT2B antagonist), or a-methylserotonin maleate (5-HT2B agonist) (both Sigma-Aldrich, Milan, Italy). After stimulation, culture supernatants were removed, centrifuged at 500g for 5 min to remove cellular debris and kept at À801C until assayed by a specific ELISA kit (R&D Systems, Abington, UK). TNF-a shedding was observed by treating microglial cells with 50 nmol/l a-methylserotonin maleate for 1 h alone or in combination with 200 nmol/l ST1942. The release of TNF-a in culture media was assayed as described previously. Primary hippocampal neurons were prepared from embryonic day 18 rat brain (Goslin and Banker, 1990; Hansen et al, 1989) . After dissection, the hippocampi were treated with 2.5% trypsin and dissociated with a flame-polished Pasteur pipette. The cells were plated onto poly-L-lysine-treated glass coverslips (2 Â 10 5 cells/well) in Minimum Essential Medium (Life Technologies Inc.) containing 10% FCS. After 2 h, the medium was substituted with Neurobasal-A/B27 (Life Technologies Inc.). After 8 h from seeding 5 mM arabinosylcytosine was added. Neuronal cell cultures contained less than 1% of astrocytes, as shown by glial fibrillary acidic protein (GFAP) staining (data not shown). For neuronmicroglia cocultures coverslips were transferred to the 24-well plates containing the microglial cells (2 Â 10 5 cells/well), facing down, on top of paraffin drops. These cultures were treated for 24 h with 0.1 or 1 mg/ml E. coli LPS alone or in combination with 50 mmol/l ST1942.
Cell viability was assessed by lactate dehydrogenase (LDH) release in the culture medium. It was measured by Cytotoxicity Detection Kit (Roche, Mannheim, Germany) according to manufacturer's protocols. Cell viability was also measured by MTT reduction essentially as described (Hansen et al, 1989) . LDH assay was performed on culture medium shared by neurons and microglia, whereas for MTT test neurons were separated from microglia before cell lysis.
RESULTS
Infarct Volume and Neurodegeneration
ST1942 is able to reduce the ischemic volume in a dosedependent way (Figure 1a) . Using the most effective dose 
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(25 mg/kg), we have analyzed the effect of different treatment schedules on the infarct lesion in C57BL/6 mice. At 48 h from ischemia, in ischemic mice receiving four doses of the drug, (schedule A) the infarct volume decreases by 61% (ST1942: 11.772.7 mm 3 ). A significant reduction of the infarct lesion is still present when the first dose is delayed to 2, 4, and 6 h after ischemia (2 h: 9.1472.9 mm Figure 1b) . A decrease, although not statistically significant, is still present when the first dose is delayed 8 h after ischemia (schedule E). The effect of a single dose of the drug given 30 min after ischemia has also been assessed 48 h after ischemia (schedule F). It reduces the ischemic lesion by 21% (saline: 29.777.8 mm 3 ; ST1942: 23.674.1 mm 3 ), a nonsignificant decrease (data not shown).
As different strains of mice may respond differently to the ischemic insult, we also analyzed the effect of ST1942 in CD1 mice. In these mice, 48 h after ischemia, the same treatment significantly reduces the ischemic lesion by 50% (saline: 105.48712 mm 3 ; ST1942: 52.70716.32 mm 3 , data not shown) indicating that ST1942 can markedly reduce the ischemic volume in both inbred (C57BL/6) and outbred (CD1) mice. Except for this experiment, all others were performed in C57BL/6 mice.
We then evaluated the effect of ischemia and ST1942 treatment on neurodegeneration to determine if neurons are actually spared by drug treatment. Typically, the ischemic protocol used induces neurodegeneration in striatum and, to a lesser extent, in cortex and hippocampus. As expected, 48 h after ischemia, Fluoro-Jade staining, a 
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C Capone et al neurodegeneration marker, reveals the presence of degenerating neurons in these brain areas. In saline-treated mice, positive cells are constantly observed in the parietal cortex and in striatum where they appear as extended clusters of positive cells (Figure 2a and c) . Several fluorescent cells are also present in hippocampus, including CA1 (Figure 2e ), CA2, CA3 (Figure 2g) , and dentate gyrus. In mice treated with ST1942, the number of degenerating cells is greatly reduced. Few positive cells are still present in cortex and striatum (Figure 2b and d) and only a few groups of fluorescent pyramidal neurons are present in hippocampus (Figure 2f and h) , showing that ST1942 markedly reduces the number of degenerating cells.
Neurological Deficits
To evaluate if the marked reduction of the ischemic lesion produces an improvement in functional impairment, neurological deficits were evaluated every day for 4 days in ischemic mice receiving saline or ST 1942 according to the same protocol as in Figures 1a and 2 except that the treatment was continued every 12 h from the 36 h time point to 84 h (schedule G). Both general and focal neurological deficits are significantly improved (Figure 3 ). The effect is apparent already at the first test at 24 h.
Gene Expression Data
To investigate the neuroprotective mechanisms of ST1942, we analyzed some genes activated by ischemia 24 and 48 h after surgery (schedules H and A, respectively) in the cortex of ischemic and sham-operated mice (Figure 4 ). With the ischemic protocol used, this brain area typically includes a portion of the lesion, as well as the penumbra, where the tissue is functionally impaired but potentially salvageable and is well suited for studying ischemic gene expression (Storini et al, 2005) . The mRNA expression of the inflammatory cytokines TNF-a and IL-1b are significantly upregulated by ischemia compared to sham-operated mice both at 24 and 48 h. ST1942 treatment significantly prevents the upregulation of these cytokines at both time points (Figure 4) .
The expression of the antiapoptotic gene Bcl-2 is decreased at 24 h in ischemic mice. At this time point, the drug treatment does not change this effect. At 48 h, instead, the expression of this protective gene is markedly enhanced by treatment with the drug. At the same time point, the ischemia-induced activation of the proapoptotic gene Bax is prevented by ST1942 treatment, which dampens its expression compared to ischemic and to sham-operated mice (Figure 4 ).
Microglia/Macrophage Cell Activation
Ischemic mice show a strong cell activation and/or infiltration of microglia/macrophages. Forty-eight hours after ischemia CD11b-positive cells are larger in size and increased in number compared to sham-operated mice. ST1942 is able to markedly reduce the number of positive cells throughout the lesioned area ( Figure 5 ).
Binding Studies
Results from binding assays indicate that ST1942 inhibits DOI binding to human 5HT2B receptors in transfected CHO cells with a K i of 2.8 Â 10 À7 . The drug does not displace DOI in non-transfected cells (data not shown).
The binding assay screening carried out (see Materials and methods) revealed that ST1942 had 410 À5 affinity for all the other binding sites assessed, including serotonin: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2C (data not shown).
Effects of ST1942 and 5-HT2B Drugs on Microglial Cells
To test the hypothesis that ST1942 can modulate the inflammatory response by acting on microglial cells, which are the inflammatory cells of the brain, we evaluated its effect on LPS-induced TNF-a release in primary microglial cells and in BV-2 microglial cell line. ST1942 dosedependently reduces TNF-a release in both primary microglia (Figure 6a ) and BV-2 cells (data not shown) challenged with LPS. The suppression of TNF-a production is not caused by any toxicity associated with ST1942 as confirmed by MTT assay and LDH release (data not shown). We then tested the ability of 5-HT2B agonists and antagonists to modify LPS-induced TNF-a release in microglia. The 5-HT2B antagonist SB204741 inhibits TNF- Figure 3 General and focal neurological score evaluation assessed daily in ischemic mice receiving saline (black line) or 25 mg/kg ST1942 (gray line) twice a day for 4 days. Mice were scored from 0 (healthy) to 28 and data are expressed as mean7SEM, n ¼ 7. Difference between curves is evaluated by two-way ANOVA for repeated measures. F interaction: **po0.01.
2-Aminotetraline in ischemic injury
C Capone et al a production in LPS-stimulated cells, whereas the 5-HT2B agonist a-methylserotonin maleate is ineffective. On the contrary, at 1 and 10 mmol/l a-methylserotonin maleate determines an increased release of TNF-a compared to control (Figure 6b ). Moreover, treatment of primary microglial cells with a-methylserotonin maleate alone for 1 h induces TNF-a release in the culture media and this effect is blocked by ST1942 (Figure 6c) . Although amethylserotonin maleate has affinity to many 5-HT receptors, our binding studies performed on a large number of receptors show that ST1942 has a very low affinity for 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, and 5-HT2C (see Materials and methods).
In cocultures of hippocampal neurons and microglia an increased release of LDH in the culture medium is observed after LPS treatment, which can be reduced by ST1942 (Figure 7a ) indicating a neuroprotective effect of this compound. No release of LDH is observed in LPS-treated microglia and neurons cultured separately (data not shown). The MTT assay confirms that neuronal death induced by LPS is significantly attenuated by ST1942 (Figure 7b ).
DISCUSSION
The present study demonstrates that the 2-aminotetraline derivative ST1942 effectively prevents tissue damage and neurological deficits in ischemic brain. The ability of the compound to reduce the ischemic lesion was shown both in C57/BL6 and in CD1 mice, that is, inbred and outbred strains. Notably, when given at 25 mg/kg, a significant reduction of ischemic volume was evidenced when the first dose was given up to 6 h after injury.
The use of Fluoro-Jade staining to show degenerating neurons allowed us to investigate whether ST1942 action could spare these cells. A marked decrease in the number of Fluoro-Jade-positive cells was observed throughout different brain areas, striatum, cortex, and hippocampus in treated mice, indicating that neurodegeneration was actually inhibited by ST1942.
An important aspect when assessing the protective effect of a compound on ischemia/reperfusion injury is the evaluation of its ability to affect functional deficits. The monitoring of general and focal neurological deficits clearly showed that ischemic mice receiving the drug, showing improvement in appearance and motor performance, were significantly protected compared to saline-treated mice. Importantly, this effect, apparent at just 24 h after ischemic injury, was persistent and observed throughout the experiment (4 days).
Thus, the data obtained clearly indicate that ST1942 has strong protective properties and a broad effective window (at least 6 h) in ischemia/reperfusion brain injury.
To identify targets of ST1942 action that can account for its neuroprotective effect in ischemia/reperfusion injury, we analyzed the cortical mRNA expression of some genes activated by ischemia/reperfusion (Storini et al, 2005) and investigated possible modulating effects of the compound at two time points from ischemia. The results show that ST1942 has anti-inflammatory and antiapoptotic properties and that inhibition of inflammation is an early target of ST1942 action. In fact ST1942 significantly reduces the upregulation of the inflammatory cytokines TNF-a and Figure 4 2-aminotetraline in ischemic injury mRNA expression of IL-1b, TNF-a, Bcl-2, and Bax determined 24 and 48 h after ischemia by real-time PCR on cortices of sham-operated or ischemic mice receiving saline (sham-operated: striped bars; ischemic: black bars) or ST1942 (25 mg/kg, sham-operated: white bars; ischemic: gray bars) at 30 min, 6, 24, and 36 h after beginning of ischemia. Data are expressed as mean7SEM (four to five mice per group) *po0.05 and **po0.01 vs corresponding sham operated, 1po0.05 and 11po0.01 vs ischemic mice receiving saline, ANOVA followed by Tukey's post hoc test.
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C Capone et al IL-1b observed as early as 24 h after injury and later on at 48 h. Instead, analysis of the expression of genes related to apoptosis (Troglio et al, 2004) revealed that 48, but not 24 h from ischemia, ST1942 decreases the expression of the proapoptotic gene Bax and increases that of the antiapoptotic Bcl-2 thus inducing a shift from a pro-to an antiapoptotic status. Notably, the decrease in Bax and the increase in Bcl-2 expression are wide and do not simply restore the expression observed in sham operated experimental groups. This may be possibly due to a modulation of Bax and Bcl-2 gene expression in astrocytes, a cell population that is activated by ischemia. Further experiments are needed to fully substantiate this hypothesis.
In the ischemic brain, microglial cells are rapidly and persistently activated, being, together with macrophages recruited from blood stream, the major effectors of the brain inflammatory response (Becher et al, 2000) . Consistently with the inflammatory gene evaluation described above, ST1942 markedly prevents the microglia/macrophages activation/recruitment further showing a potent anti-inflammatory action. The complex role of the inflammatory response in acute brain injury and specifically of the inflammatory cells is still an open question (del Zoppo et al, 2001; Feuerstein and Wang, 2001; Neumann et al, 2006) . Both our in vivo and in vitro data indicate that microglial cells are a target of the aminotetraline protective action. Actually, the drug effectively prevents LPS-induced neuronal cell death in neuron-microglia cocultures. Moreover, the data obtained on microglial cell cultures show that ST1942 exerts its anti-inflammatory effect by direct action on these cells. In fact, exposure to ST1942 induces a dose-dependent decrease in LPS-induced TNF-a release. Taking into account that our aminotetraline derivative binds 5-HT2B receptors, we tested the hypothesis that it could act through these receptors. Actually, similarly to ST1942, a 5-HT2B antagonist inhibits TNF-a release in LPS-treated microglia. In addition, ST1942 is able to inhibit TNF-a shedding induced in microglia by a 5-HT2B agonist. Although thus far the localization of these 5-HT receptor subtypes in the brain is largely unknown and further studies are ongoing to better 2-Aminotetraline in ischemic injury C Capone et al define their specific function (Leysen, 2004) , these data indicate that they may be involved in the control of inflammatory molecule release. Actually serotonin is known to be involved in a wide spectrum of immune response modulatory activity (Hellstrand et al, 1993; Kubera et al, 2000 Kubera et al, , 2005 Young and Matthews, 1995) . Interestingly, one recent study proposes a specific involvement of 5-HT2B receptors in the regulation of inflammatory cytokine production from blood cells (Kubera et al, 2005) , and a second one shows that stimulation of 5-HT2B receptors leads to a TNF-a converting enzyme-dependent TNF-a release, thus linking activation of these receptors to an increased expression of pro-inflammatory cytokines (Pietri et al, 2005) .
The present findings show that ST1942 exerts strong neuroprotective action in ischemia/reperfusion brain injury with a broad time-window of efficacy. Its anti-inflammatory properties, possibly owing to its activity on 5-HT2B receptors, may well account for its antiapoptotic protective actions. Figure 6 Inhibition of TNF-a release by ST1942 and SB204741 in primary microglia. Primary microglial cells were stimulated with LPS (50 ng/ml) in the absence or presence of: ST1942 (a); SB204741 or amethylserotonin maleate (b). After a 1-h incubation, media were collected and analyzed for TNF-a by ELISA. (c) Primary microglial cells were stimulated for 1 h with a-methylserotonin maleate (50 nM) alone or in combination with ST1942 (200 nM) and TNF-a release was measured as described previously. *po0.05; **po0.01 vs controls (cultures treated with LPS alone in a and b or untreated cells in c). ANOVA with Bonferronicorrected t-test. Data shown are means7SEM of three determinations. 
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